Physician profile
Timothy Mims
NPI 1083692982
$10,896.70
in general payments reported to CMS, 2019-2025
33 companies · $307 in 2025
The $307 reported for 2025 was less than what a typical Pain Medicine (Anesthesiology) provider received nationally (typical 2025 total: $458).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,826 · 2020: $1,821 · 2021: $1,193 · 2022: $2,320 · 2023: $689 · 2024: $742 · 2025: $307.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,738.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,737.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nevro Corp. | $2,526.58 | 2019-2024 | Senza |
| Medtronic USA, INC. | $2,043.68 | 2019-2020 | |
| Relievant Medsystems, INC. | $1,633.35 | 2022 | |
| Abbott Laboratories | $663.50 | 2019-2025 | Eterna, Proclaim |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $640.59 | 2020-2024 | Relistor |
| Si-Bone, INC. | $510.20 | 2019-2025 | |
| Boston Scientific Corporation | $436.33 | 2019-2022 | |
| Collegium Pharmaceutical, INC. | $420.53 | 2019-2022 | |
| Scilex Pharmaceuticals INC. | $293.19 | 2019-2024 | Ztlido |
| Pacira Therapeutics, INC. | $243.23 | 2019-2021 | |
| Stimwave Technologies Incorporated | $239.46 | 2020-2021 | |
| Mdd US Operations, LLC | $157.21 | 2019-2020 | |
| Grt US Holding, INC. | $154.32 | 2020-2021 | |
| Vertos Medical, INC. | $137.64 | 2022 | |
| Medtronic, INC. | $90.51 | 2021 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Redhill Biopharma INC. | $83.75 | 2020-2021 | |
| Flowonix Medical Incorporated | $67.91 | 2019-2020 | |
| Abbvie INC. | $62.95 | 2025 | |
| Ibsa Pharma INC. | $60.68 | 2021-2022 | |
| Arbor Pharmaceuticals, INC. | $57.55 | 2020-2021 | |
| Astrazeneca Pharmaceuticals LP | $47.14 | 2019-2020 | |
| Protega Pharmaceutials INC | $41.97 | 2022 | |
| Amgen INC. | $41.66 | 2020-2022 | |
| Vertex Pharmaceuticals Incorporated | $40.38 | 2024-2025 | |
| Tonix Medicines, INC. | $39.42 | 2025 | Tonmya |
| Pfizer INC. | $38.31 | 2019-2023 | |
| Daiichi Sankyo INC. | $30.10 | 2019 | |
| Bioventus LLC | $26.05 | 2020-2022 | |
| Amneal Pharmaceuticals LLC | $16.55 | 2023 | Lyvispah |
| Pacira Pharmaceuticals Incorporated | $14.64 | 2022 | |
| Zyla Life Sciences, INC. | $13.81 | 2019 | |
| Lilly USA, LLC | $11.95 | 2020 | |
| Depuy Synthes Sales INC. | $11.56 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Mims listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.